|
A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma (ECOG E2805):
- No history of distant metastases
- No prior anti-cancer therapy is permitted in either the adjuvant or neoadjuvant setting
- Can be registered either pre or post-surgery
|
